Sepsis
Drug research and approvals for sepsis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 381 studies of sepsis are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, and FDA has 0 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 381
- Trials authorized in Canada: 15
- FDA orphan approvals: 0
- EU medicines: 0
- AI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor DecisionsNCT07950943 · Not applicable · Nanjing University · starts Nov 5, 2026
- A Mixed-Method Study for Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care UnitsNCT07941856 · Not applicable · Peking University First Hospital · starts Nov 1, 2024
- Immune Response Profiling in SepsisNCT07937839 · Not reported · National University Hospital, Singapore · starts Jun 15, 2026
- Effect of Rutin and Vitamin C on Outcomes in Adults With Sepsis Admitted to the Intensive Care UnitNCT07922213 · Not applicable · Ain Shams University · starts Aug 1, 2026
- Oral Switch in Bloodstream Infections in Immunocompromised ChildrenNCT07923266 · Phase 4 · Copenhagen University Hospital, Rigshospitalet · starts Nov 9, 2026
- Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn PatientsNCT07914205 · Not reported · Center for Traumatology and Major Burns, Ben Arous · starts Aug 1, 2026
- Middle East Study of Infections in Patients With Hematological MalignanciesNCT07900542 · Not reported · Hamad Medical Corporation · starts Sep 15, 2024
- A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving…NCT07898462 · Phase 3 · The George Institute · starts Oct 16, 2026
- Clinical Value of EMR3 in Sepsis Diagnosis, Monitoring, and Prognosis: A Multicenter Prospective Observational StudyNCT07896018 · Not reported · Sir Run Run Shaw Hospital · starts Nov 1, 2026
Approved 13
- Drotrecogin alfa (activated)Coagulation factor VIII inhibitor
- ImipenemBacterial penicillin-binding protein inhibitor
- NorepinephrineAdrenergic receptor agonist
- CeftriaxoneBacterial penicillin-binding protein inhibitor
- AmpicillinBacterial penicillin-binding protein inhibitor
- MetronidazoleDNA inhibitor
- CilastatinRenal dipeptidase inhibitor
- AmikacinBacterial 70S ribosome inhibitor
- Clindamycin phosphateBacterial 70S ribosome inhibitor
- VancomycinPeptidoglycan inhibitor
- AztreonamBacterial penicillin-binding protein inhibitor
- CefazolinBacterial penicillin-binding protein inhibitor
- VasopressinVasopressin receptor agonist
Phase 3 12 of 38
- Ascorbic acidSupplement
- Glutamine
- HeparinAntithrombin-III activator
- Nitric oxideSoluble guanylate cyclase activator
- AcetaminophenCyclooxygenase inhibitor
- GentamicinBacterial 70S ribosome inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- TazobactamBacterial beta-lactamase TEM inhibitor
- MeropenemBacterial penicillin-binding protein inhibitor
- PiperacillinBacterial penicillin-binding protein inhibitor
- Albumin humanBilirubin sequestering agent
- ResatorvidToll-like receptor 4 inhibitor
Phase 2 12 of 23
- PagibaximabLipoteichoic acid inhibitor
- UbidecarenoneSupplement
- Zinc sulfate
- Talactoferrin alfa
- EpirubicinDNA inhibitor
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- ChlorhexidineCell membrane inhibitor
- GranisetronSerotonin 3a (5-HT3a) receptor antagonist
- CalcitriolVitamin D receptor agonist
- RosuvastatinHMG-CoA reductase inhibitor
- AtorvastatinHMG-CoA reductase inhibitor
- SimvastatinHMG-CoA reductase inhibitor
Phase 1 or earlier 12 of 22
- RelebactamBeta-lactamase SHV-1 inhibitor
- MelatoninMelatonin receptor agonist
- Methylene blue cationReducing agent
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- MidodrineAdrenergic receptor alpha-1 agonist
- DexamethasoneGlucocorticoid receptor agonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- NelfinavirHuman immunodeficiency virus type 1 protease inhibitor
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- Clavulanic acidBacterial beta-lactamase TEM inhibitor
- TicarcillinBacterial penicillin-binding protein inhibitor
How its trials ended
1,566 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 277 whose ending is known, 31% met their primary endpoint, 16% missed it and 53% stopped early.
- Completed, result not reported63541%
- Status unknown33822%
- Ongoing31620%
- Met its primary endpoint865%
- Stopped: other or unclear835%
- Missed its primary endpoint433%
- Stopped: enrollment or feasibility403%
- Stopped: lack of efficacy101%
- Stopped: funding6<1%
- Stopped: sponsor or business decision5<1%
- Stopped: safety4<1%
| Dec 15, 2025 | Beta-blocker therapy versus standard care in patients with septic shock: a pilot randomized controlled trial utilizing predictive enrichment with point-of-care…Esmolol | London Health Sciences Centre | Ongoing |
| Jul 15, 2025 | The nicu antibiotics and outcomes trial (NANO)Ampicillin / Gentamicin | The Governors of The University of Alberta | Closed |
| Sep 20, 2023 | Amulticenter, randomized, double-blind, placebo-controlled, four-arm, parallel-group, dose-finding, phase 2b study to investigate the safety and efficacy of…TIN816 | Novartis Pharmaceuticals | Closed |
| Nov 30, 2022 | Intravenous dnase i for the treatment of sepsis: a phase I safety and feasibility study in icu patientsPulmozyme | McMaster University | Ongoing |
| Mar 9, 2022 | Energy metabolism of septic heartPalmitate 11C / Actetate 11C / Cyclodx | Ciusss De L'Estrie - Centre Hospitalier Universitaire De Sherbrooke | Pending |
| Apr 26, 2021 | Pragmatic pediatric trial of balanced versus normal saline fluids in sepsis (prompt bolus)Plasma-lyte a/ Lactated ringer's/ Sodium chloride | Governors of The University of Calgary | Ongoing |
| Mar 3, 2021 | The amethyst trial - advanced mesenchymal enhanced cell therapy for septic patientsCryopreserved, genetically modified allogeneic mesenchymal stromal cells | Northern Therapeutics Inc. | Closed |
| Sep 11, 2020 | A randomized, double-blind, placebo-controlled, two-arm parallel-group, multi-center phase 3 pivotal trial to investigate the efficacy and safety of…Recombinant human alkaline phosphatase (RECAP) | Am-Pharma B.V. | Closed |
| Jun 5, 2020 | Lessening organ dysfunction with vitamin C ¿ covid (lovit-covid)Vitamin C | Centre De Recherche Du Centre Hospitalier Universitaire De Sherbrooke | Ongoing |
| Nov 22, 2018 | A crossover, cluster randomised controlled trial of selective decontamination of the digestive tract in intensive care unit patients (SUDDICU)Nystatin-colistin-tobramycin | Sunnybrook Research Institute | Closed |
| Feb 19, 2015 | Bovine lactoferrinPrevention of late-onset sepsis in very low birth weight infants | Metrodora Therapeutics, LLC | Designated |
| Aug 3, 2000 | Chimeric, humanized monoclonal antibody to staphylococcusProphylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants. | Biosynexus, Inc. | Designated |
| Dec 20, 1993 | BeractantTreatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension… | Ross Laboratories | Designated |
| Nov 4, 1985 | Monoclonal antiendotoxin antibody XMMEn-0e5Treatment of patients with gram-negative sepsis which has progressed to shock. | Pfizer, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA